| Literature DB >> 29444683 |
Samir A E Bashandy1, Hossam Ebaid2,3, Sherif A Abdelmottaleb Moussa4,5, Ibrahim M Alhazza6, Iftekhar Hassan7, Abdulaziz Alaamer4, Jameel Al Tamimi1.
Abstract
BACKGROUND: The liver disease is one of the most important traditional public health problems in Egypt. Oxidative stress is attributed to such pathological condition that further contributes to the initiation and progression of liver injury. In the present study, we have investigated if the strong antioxidant power of Nicotinamide (NA), Vitamin B2 (VB2), and Vitamin C (VC) can ameliorate TAA-induced oxidative stress-mediated liver injury in the rats.Entities:
Keywords: Hepatotoxicity; Inflammatory markers; Lipid profile; Nicotinamide; Oxidative stress; Thioacetamide; Vitamin B2; Vitamin C
Mesh:
Substances:
Year: 2018 PMID: 29444683 PMCID: PMC5813429 DOI: 10.1186/s12944-018-0674-z
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Effect of Nicotinamide, Vitamin B2 and Vitamin C on liver function parameters in plasma of thioactamide treated rats
| Treatment Parameter | Control | TAA | TAA + NA | TAA + VB2 | TAA + VC | TAA + NA,VB2,VC |
|---|---|---|---|---|---|---|
| AST(U/l) | 46.53 ± 1.08 | 269.36 ± 11.75a | 137.64 ± 6.83a,b | 142.43 ± 7.76a,b | 170.34 ± 7.33a,b | 95.17 ± 4.59a,b,c |
| ALT(U/l) | 23.17 ± 1.34 | 153.46 ± 8.63a | 114.56 ± 4.78a,b | 109.89 ± 9.32a,b | 94.57 ± 3.21a,b | 65.46 ± 1.96a,b,c |
| ALP(U/l) | 150.46 ± 10.06 | 676.35 ± 21.67a | 470.48 ± 26.41a,b | 418.34 ± 15.68a,b | 580.41 ± 19.73a,b | 242.00 ± 15.47a,b,c |
| LDH | 212.55 ± 8.69 | 802.40 ± 4.75a | 512.07 ± 18.67a,b | 450.82 ± 14.25a,b | 478.16 ± 17.56a,b | 275.44 ± 12.49a,b,c |
| Total bilirubin(mg/dl) | 0.43 ± 0.01 | 0.91 ± 0.03a | 0.63 ± 0.01a,b | 0.70 ± 0.04a,b | 0.66 ± 0.03a,b | 0.54 ± 0.02a,b,c |
| Total protein(g/dl) | 7.34 ± 1.58 | 5.27 ± 0.10a | 5.88 ± 0.19a,b | 6.09 ± 0.27a,b | 6.47 ± 0.34a,b | 7.55 ± 0.10a,b,c |
aSignificant difference from control
bSignificant difference from TAA group
cSignificant difference from TAA + NA, TAA + VB2, TAA + VC
Effect of Nicotinamide,Vitamin B2 and Vitamin C on plasma lipid profile of rats treated with thioacetamide
| Control | TAA | TAA + NA | TAA + VB2 | TAA + VC | TAA + NA,VB2, VC | |
|---|---|---|---|---|---|---|
| Cholesterol(mg/dl) | 70.33 ± 3.45 | 158.58 ± 5.67a | 135.11 ± 4.39a,b | 114.37 ± 7.01a,b | 102.44 ± 3.12a,b | 84.37 ± 2.49a,b,c |
| Triglycerides (mg/dl) | 64.58 ± 3.16 | 190.86 ± 8.23a | 159.11 ± 4.23a,b | 140.27 ± 3.55a,b | 96.75 ± 2.81a,b | 72.60 ± 5.36b,c |
| HDL (mg/dl) | 33.62 ± 1.38 | 26.09 ± 1.43a | 31.96 ± 1.02 | 30.25 ± 0.78 | 30.43 ± 1.54 | 32.48 ± 2.57 |
| LDL(mg/dl) | 49.72 ± 1.62 | 100.83 ± 3.58a,b | 70.39 ± 3.08a,b | 76.00 ± 2.51a,b | 66.42 ± 2.81a,b | 53.17 ± 1.94b,c |
aSignificant difference from control (P
bSignificant difference from TAA group
cSignificant difference from TAA + NA, TAA + VB2, TAA + VC
Effect of Nicotinamide, Vitamin b2 and Vitamin C on hepatic MDA (nmol/mg), GSH (μmol/g tissue), catalase (U/g tissue), SOD (U/g tissue), NO (nmol/g,Hydroxyproline (Ug/g tissue) and plasma TNF-α (Pg/ml)
| Control | TAA | TAA + NA | TAA + VB2 | TAA + VC | TAA + NA,VB2,VC | |
|---|---|---|---|---|---|---|
| MDA | 6.43 ± 0.23 | 11.78 ± 0.45a | 8.59 ± 0.42a,b | 9.04 ± 0.47a,b | 8.16 ± 0.32a,b | 7.35 ± 0.16a,b,c |
| GSH | 32.78 ± 1.06 | 19.68 ± .0.30a | 23.79 ± 0.51a,b | 23.55 ± 1.02a,b | 25.82 ± 0.54a,b | 29.48 ± 0.49b,c |
| Catalase | 503.17 ± 30.00 | 266.84 ± 22.57a | 400.46 ± 20.33a,b | 370.16 ± 12.93a,b | 395.00 ± 18.71a,b | 468.52 ± 8.75b,c |
| SOD | 275.43 ± 8.41 | 131.73 ± 6.98a | 200.17 ± 11.07a,b | 180.00 ± 4.51a,b | 188.72 ± 9.12a,b | 249.84 ± 8.26b,c |
| NO | 65.78 ± 3.18 | 127.34 ± 6.38a | 80.67 ± 3.74a,b | 93.08 ± 4.11a,b | 88.71 ± 3.53a,b | 74.96 ± 2.56b |
| H.Prol | 112.47 ± 6.32 | 763.71 ± 21.49a | 426.85 ± 10.65a,b | 512.67 ± 17.53a,b | 459.27 ± 13.89a,b | 342.79 ± 8.29a,b,c |
| TNF-α | 12.42 ± 0.25 | 76.28 ± 1.03a | 44.90 ± 0.56a,b | 60.85 ± 0.52a,b | 53.67 ± 0.36a,b | 36.42 ± 0.11a,b,c |
aSignificant difference from control
bSignificant difference from TAA group
cSignificant difference from TAA + NA, TAA + VB2, TAA + VC
Fig. 1Representative photos of the hepatic tissues from the control and the various treated groups. Arrow: Dilated sinusoids; Black arrow head: Vacuolated hepatocytes; Red arrow head: Inflammatory cell infiltration; Yellow arrow head: Vesiculated nucleus; Blue arrow head: Normal nucleus
Fig. 2Showing putative mechanism of TAA-toxicity amelioration by the proposed combination of the vitamins